Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Novartis | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Novartis

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novartis

4Q Revenues: $9.9 billion (+6%)

4Q Earnings: $931 million (-42%)

YTD Revenues: $39.8 billion (+8%)

YTD Earnings: $12.0 billion (+66%)

Comments: U.S. pharmaceutical sales were down 21% in the quarter, due to the withdrawal of Zelnorm and generic competition for hypertension drug Lotrel. Earnings in the quarter were also impacted by a $444 million restructuring charge, as a result of 2,500 job cuts. The company hopes to save $1.6 billion in costs each year by 2010. Results include pre-tax divestment gains of $5.8 billion from Medical Nutrition (until June 30) and Gerber (until August 31). Sales growth was driven by Vaccines and Diagnostics and Sandoz, up 52% FY to $1.4 billion, and 20% FY to $7.2 billion, respectively. Diovan sales were $1.4 billion in the quarter, up 12%, and $5.0 billion for the year, up 16%. Gleevec/Glivec sales in the quarter were $800 million, up 12% and for the year were $3.1 billion, up 14%. R&D expenses for the year were up 19% to $5.1 billion, accounting for 21% of sales.  

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters